Conclusions 
 
Conclusions.pdf View Download
 
I.A.Egorov, A.G.Serbin, V.V.Rossikhin, A.V.Artemov, V.A.Sorokin, E.I.Oleynik, V.P.Shetilov, L.P.Pelichova, I.G.Vakaryuk.
 
 
Scientific and treatment center for cancer curing PHOENIX
 
National University of Pharmacy (NUPh) of Ukraine
 
Kharkiv Medical Academy of Postgraduate Education
 
Filatov Institute of eye diseases and tissue AMS of Ukraine
 

 

 

FLARAXIN should be recommended to the wide clinical application as a cytostatics drug, which proved to be effective in patients with cancer of the following organs: cerebrum (brain) cancer, melanoma, melanoblastoma, breast cancer, mammary gland cancer, lungs cancer, stomach cancer, bladder cancer, colorectal cancer, colon cancer, uterus cancer, cervix cancer, ovaries cancer, neck of womb and womb cancer, bowels cancer, prostate gland, adenoma, mediastinal cancer, non-malignant neoplasm, improving general state of patients, not suppressing hemopoiesis and does not have an adverse effect on CNS, does not disrupt the function of the vitally important organs (liver, kidneys, cardiovascular system (CVS)) , with very rare exception of side effects. 
 
FLARAXIN can be administered not only to advanced cancer patients, but also for curable patients in combination with the radiological, and in combination with chemo-regimens and surgery (as prevention of cancer recurrence).
 
The clinical administration of drug FLARAXIN is recommended by us in the following cases:
 
The largest benefit from FLARAXIN is achieved in patients with the pretumorous proliferating processes, and also in the persons, with the minimum tumor process, after the radical surgical treatment, when it is necessary to conduct the restoration of the anti-tumor resistance of organism and its homeostatic mechanisms;

FLARAXIN combined together with poly-Chemotherapy proved to be highly effective among the patients with heavy cancer process due to its specific anti-cancerous action and protective properties. Treatment with Flaraxin can be done in mono and complex therapy; moreover FLARAXIN can be administered before Poly-Chemotherapy, in periods between treatment cycles of Chemotherapy, and for stabilization after positive results achieved by standard therapy due to its minimum toxicity and ability to stop metastatic spreading. Flaraxin exists in intravenous injections, capsules, tablets for oral and cones (suppository) for rectal and vaginal application.
FLARAXIN is compatible with many anti-cancer drugs according to it’s chemical properties, with exception of those that contain iron (Fe) inside, because Flaraxin can form a complexes with iron (Fe).

 

Application of FLARAXIN to Chemotherapy is able to decrease side effects:
  • Cardiotoxicity, caused by the activation lipooxygenases with characteristic of the antibiotics of the anthracyclines line;
  • Neurotoxity is similar to the preparations of the [vinka]- class (Vincristine, Vinblastine);
  • Pa-pyramidal disorders and syndrome of “orthostatic hypotension” are similar to Fluorineuracil;
  • Myelotoxic effect and immunodepression are similar to alkylating preparations.

 

Summarizing 8 years of our work experience we suggest to include FLARAXIN in different treatment procedures of oncological patients.

The treatment methods of the oncological patients are accompanied by powerful immune suppression, which suppresses the function of immune system in considerable extent, locking the vicious circle of the tumor process.

With the administration of FLARAXIN before the chemotherapy it is necessary to consider some of its special features. Thus, for instance, under Flaraxin influence on tumor cells they become more vulnerable to the factors of natural anti-tumor immunity and anti-tumor cytostatics. Therefore for the more effective treatment by FLARAXIN it is necessary to do analysis of initial immunobiochemical indices of patient, with aim to compare them after treatment by Flaraxin.

FLARAXIN should be assigned at the low level of the cytotoxic activity of the natural killers (lower than 40% - it is compulsory, from 50 to 55% - preferably); with the presence of initial non-protein SH-groups, in the blood serum (spontaneous dysproteinemia with the autoimmune aggression); and also during the disturbance of the oxidation-reduction (SH-SS) potential of serum proteins. Frequently all these disturbances are combined with each other.

If 8 assigned injections of FLARAXIN normalized the existing disturbances, noted above, then it is possible to begin chemotherapy. In case the optimal immunobiochemical indices are not achieved yet after 8 injections however background dynamics is positive, i.e., it is indicated to assign additional 8 injections. If it is not possible to perform at least one of the given immunobiochemical tests then It can be seen by the clinical picture during treatment course.

Thus, with the noticeable subjective improvement after the first 8 injections of FLARAXIN, it makes sense to continue with additional 8 injections. If no subjective signs of improvement are seen, it is suggested to stop the treatment. If patient experiences intolerance to the drug, it is necessary to stop injections. In such cases, it is suggested to combine FLARAXIN together with histamines drugs that is able to prevent allergic reaction of organism (Kenolog, Suprastin, Chloropyramine, etc) or to conduct several sessions of Plasmapheresis.

It is desirable to begin immediately with treatment by FLARAXIN after the end of Chemotherapy, especially if the immunobiochemical indices reduction is seen. In case of second-line Chemotherapy is planned, and then FLARAXIN should be given to achieve a maximum improvement of immunobiochemical indices. Low immunobiochemical indices are the main indication to assign extra 1 or 2 additional courses of Flaraxin.

Substantially the cancer therapy is the immunological problem which is based on the formation of antibodies, in response to the complex antigens of the oncologic-associated proteins and medicinal substances. If immunobiochemical indices are clearly reduced, then the use of plasmapheresis is an important component of medicinal therapy and it is desirable to assign the treatment after repeated courses of poly-Chemotherapy. In this case the determination of the initial non-protein SH-groups in the blood serum is most informative. Their appearance testifies about necessity for the assignment of Plasmapheresis. Function of plasmapheresis can sometimes be replaces by treatment with FLARAXIN between the chemotherapy courses, since FLARAXIN is able to have link with immune complexes.

Plasmapheresis is necessary if negative immunobiochemical indices (especially non-protein SH-groups) are registered after combined treatment of chemotherapy with FLARAXIN. Number of plasmapheresis courses can vary depending on the level of the immunological disturbances (disappearance of the SH-groups serves as control indication). In case of fractional plasmapheresis is applied then 5 up to 10 sessions are necessary together with blood purification (500 ml each session).
 
 Assigning of FLARAXIN strengthens the chemotherapy effect, mover, in case the drug’s transference is satisfactory then the dose reduction is not advisable.
Lower dose of chemotherapy with FLARAXIN combination are recommended in patients with diseases which diminish the effect of intensive chemotherapy. When FLARAXIN is assigned to heavy cancer patients, Chemotherapy should be given at lower doses (1/5 -1/10) in order to improve oncolytic action of FLARAXIN. In this case it is recommended to assign the chemical drug not used to the patient before treatment with FLARAXIN.
The duration of the joint application of FLARAXIN and the chemical preparations must be determined by clinical picture and immunobiochemical indices of patient. If each such course is accompanied by the normalization of immunobiochemical indices, then the combination of chemotherapy and FLARAXIN should be continued. Experience suggests 1-2 courses of FLARAXIN combined with chemotherapy plus one additional course after the end of chemotherapy in the subsequent year as an ideal scheme.
The duration of the joint application of FLARAXIN and the chemical preparations must be determined by clinical picture and immunobiochemical indices of patient. If each such course is accompanied by the normalization of immunobiochemical indices, then the combination of chemotherapy and FLARAXIN should be continued. Experience suggests 1-2 courses of FLARAXIN combined with chemotherapy plus one additional course after the end of chemotherapy in the subsequent year as an ideal scheme.
The application of FLARAXIN is not expedient in case of the following diseases: blood cancer, sarcoma of bone tissues, extensive liver cancer and extensive kidneys cancer.

FLARAXIN is effective with the following diseases: brain cancer, melanoma,  melanoblastoma, breast cancer, lung cancer, mammary gland cancer, uterus cancer, cervix cancer, ovaries cancer, bowels cancer, neck of womb cancer, womb cancer, prostate gland cancer, adenoma, mediastinal cancer, colorectal cancer, colon cancer, stomach cancer, bladder cancer, non-malignant neoplasm, which are equivalent to 90% of a total quantity of oncological diseases. FLARAXIN is most effective in the cases of the small tumors, when vital organs (liver, kidneys) are partly defeated. In these cases the complete reduction of tumor can be reached.

 

 

Head of the Botany Department

of National University of Pharmacy

of Ukraine                                                                                         Prof. Doctor of pharmacy A.G.SERBIN

Head of the Urology Department

of Kharkiv Medical Academy

of Postgraduate Education                                                                  Prof. DMS V.V.ROSSIKHIN

Professor of the Department for Drugs Technology

of National University of Pharmacy

of Ukraine                                                                                         Doctor of pharmacy I.E.EGOROV

Docent of the Oncology Department

of Zaporizhzhia Institute for Advanced Medical Training                         DMS V.A.SOROKIN

Docent of the Oncology Department

of Odessa SRI (Scientific Research Institute)

of Ophthalmology im.Filatova                                                              DMS A.V.ARTEMOV

 

 

Oncologist                                                                                        V.P.SHETILOV

Oncologist                                                                                        E.I.OLEYNIK

Oncologist                                                                                        L.P.PELIHOVA
 
  


Stccc Phoenix is looking for
doctors and medical centers around the world to work together ,to bring cancer into absolute remission ?
You can contact us:
Contact information